Showing 531-540 of 739 results for "".
- Allergy-Friendly Detergents Safe for Atopic Dermatitis Patientshttps://practicaldermatology.com/news/allergy-friendly-detergents-safe-atopic-dermatitis-patients/2470779/A recent clinical study found that two laundry detergents marketed for sensitive skin do not negatively impact the skin microbiome or worsen symptoms of atopic dermatitis (AD). The study was conducted in 41 participants diagnosed with AD. For the present study, the researchers evaluated th
- Meta-analysis: Omalizumab Alleviates Psychiatric Comorbidities of Chronic Spontaneous Urticariahttps://practicaldermatology.com/news/meta-analysis-omalizumab-alleviates-psychiatric-comorbidities-chronic-spontaneous-urticaria/2462572/A new review suggests that omalizumab was associated with a reduction in psychiatric cormidities in a number of different studies and settings. The systematic review and meta-analysis sourght to assess the clinical impacts of omalizumab on depression, anxiety, and sleep disturbances in p
- Language Barriers Linked to Underdiagnosis of Eczema and Other Allergic Conditionshttps://practicaldermatology.com/news/language-barriers-linked-to-underdiagnosis-of-eczema-and-other-allergic-conditions/2462128/
- New RNA Monitoring Method May Allow for Early Diagnosis of AD in Infantshttps://practicaldermatology.com/news/new-rna-monitoring-method-may-allow-for-early-diagnosis-of-ad-in-infants/2461771/A novel monitoring method that enables human skin transcriptome analysis of the mRNA in sebum) collected from the skin using a simple oil-blotting film may help diagnose atopic dermatitis earlier than is currently possible. According to a newstudy
- Meet Zerigo 2.0: Upgraded System Allows Patients to Better Manage Psoriasis and Eczema at Homehttps://practicaldermatology.com/news/meet-zerigo-20-upgraded-system-allows-patients-to-better-manage-psoriasis-and-eczema-at-home-2/2461681/Zerigo Health is rolling out the Zerigo 2.0 ecosystem, the newest iteration of its digital health platform for the treatment and management of chronic skin conditions like eczema and psoriasis to employers, health plans, and their provide
- The National Eczema Association and Pediatric Dermatology Research Alliance Receive Collaborative Engagement Award from PCORIhttps://practicaldermatology.com/news/the-national-eczema-association-and-pediatric-dermatology-research-alliance-receive-collaborative-engagement-award-from-pcori/2461041/The
- AnaptysBio, Inc.'s IL-33-Blocker Cleared for Phase 2a Trials in AD, Peanut Allergyhttps://practicaldermatology.com/news/anaptysbio-incs-il-33-blocker-cleared-for-phase-2a-trials-in-ad-peanut-allergy/2458347/The United Kingdom Medicines and Healthcare Products Regulatory Agency has green lighted a Phase 2a clinical trial for AnaptysBio, Inc.’s ANB020 for the treatment of adults with moderate-to-severe atopic dermatitis. The United States Food and Drug Ad
- Allergan Vet Julian S. Gangolli Joins Revance's Board of Directorshttps://practicaldermatology.com/news/allergan-vet-julian-s-gangolli-joins-revances-board-of-directors/2458508/Julian S. Gangolli, President, North America, of GW Pharmaceuticals plc, is now on Revance's Board of Directors and will serve as a member of the Audit Committee, effective July 1, 2016. He will help Revance progress toward regulatory approv
- Provectus Biopharmaceuticals, Pfizer Receive Patent Allowance for Use of PV-10 in Combination with Systemic Immunotherapy Agents in Treatment of Cancerhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-pfizer-receive-patent-allowance-for-use-of-pv-10-in-combination-with-systemic-immunotherapy-agents-in-treatment-of-cancer/2458962/Provectus Biopharmaceuticals, Inc., a clinical-stage oncology and dermatology biopharmaceutical company, announced today that it has received from the US Patent and Trademark Office a N
- Provectus Biopharmaceuticals' Novel Synthesis Patent Application Allowed by Chinese Patent Officehttps://practicaldermatology.com/news/provectus-biopharmaceuticals-novel-synthesis-patent-application-allowed-by-chinese-patent-office/2459017/Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company (